Teva announced the launch of Oral Transmucosal Fentanyl Citrate (OTFC) Lozenges, the generic version of Cephalon‘s Actiq

RELATED: Opioid Equianalgesic Doses

Actiq is indicated for breakthrough cancer pain in patients aged ≥16 years who are receiving and are tolerant to opioids (opioid tolerance is defined as taking at least 60mg of morphine/day, transdermal fentanyl 25mcg/hr,  at least 30mg of oral oxycodone daily, at least 8 mg of oral hydromorphone daily, at least 25mg oral oxymorphone daily, or an equianalgesic dose of another opioid daily for a week or longer). It is a pure opioid agonist whose principal therapeutic action is analgesia.

Oral Transmucosal Fentanyl Citrate Lozenges are available as 200mcg, 400mcg, 600mcg, 800mcg, 1200mcg, and 1600mcg strengths in 1×30 blister packs.

For more information call (888) 838-2872 or visit TevaGenerics.com.